Litchlab, a contract development and manufacturing organization (CDMO) specialized in drug delivery innovation, officially announces the launch of its Hydrogel Drug Delivery Technology Platform, offering integrated CDMO services for global pharmaceutical and biotech partners. This platform enables end-to-end support — from formulation design and scale-up to GMP production and regulatory submission — tailored to hydrogel-based therapeutics.
As the pharmaceutical industry moves toward long-acting formulations, minimally invasive therapies, and biocompatible delivery systems, hydrogels have emerged as a key enabling material. Characterized by high water content, tunable mechanical properties, and compatibility with biological tissues, hydrogels are now extensively explored in oncology, regenerative medicine, ophthalmology, dermatology, and mRNA vaccine delivery.
Litchlab’s Technical Strength in Hydrogel Systems
Litchlab’s hydrogel platform supports a wide array of natural, synthetic, and composite polymer systems to meet diverse therapeutic needs:
Natural Polymers: Alginate, gelatin, hyaluronic acid, chitosan
Synthetic Polymers: PEG, PLGA-PEG, PVA, poly(acrylate) hydrogels
Smart Composite Hydrogels: Featuring thermo-, pH-, or enzyme-responsive properties for on-demand drug release
Versatile Drug Delivery Modalities
Injectable in situ-gelling systems for minimally invasive delivery
Implantable hydrogel matrices for local, sustained release
Nano/micro hydrogel particles for subcutaneous, ocular, or transdermal use
Hybrid platforms combining liposomes, polymeric nanoparticles, or biologics for synergistic delivery
Broad Payload Compatibility
Hydrogels can encapsulate and deliver a wide range of therapeutics, including:
Small molecules
Peptides and proteins
Monoclonal antibodies (mAbs)
Vaccines and nucleic acids (siRNA, mRNA)
Extracellular vesicles (EVs) or living cells
End-to-End CDMO Capabilities
Litchlab offers full-spectrum services for hydrogel-based drug products:
Aseptic process development and filling technologies
Tunable crosslinking strategies (chemical, ionic, enzymatic)
Customizable viscoelasticity, gelation time, and release kinetics
Scale-up from grams to kilograms for clinical-grade manufacturing
Sterile liquids, lyophilized powders, injectable gels, or topical formulations
Regulatory & Analytical Support
Comprehensive rheology, swelling, and drug release profiling
Biocompatibility, degradation, and toxicology evaluations
Stability studies per ICH guidelines
Regulatory documentation preparation for IND, IMPD, and NDA filings (FDA, EMA, NMPA)
Applications Across Therapeutic Frontiers
| Field | Representative Use Cases |
|---|---|
| Oncology | Post-surgical in situ chemotherapy gels |
| Pain Management | Long-acting local anesthetic release systems |
| Regenerative Medicine | Growth factor-releasing scaffolds and cell-laden gels |
| Vaccines | Hydrogel-based mRNA vaccine adjuvants |
| Ophthalmology & Dermatology | Controlled-release eye drops and wound healing hydrogels |
Why Litchlab?
End-to-end hydrogel CDMO solutions from R&D to GMP
Extensive experience in polymer design, aseptic formulation, and release control
Seamless integration with lipid nanoparticles, microspheres, or micelles
Full lifecycle regulatory support for global clinical development
📨 To learn more about how Litchlab can accelerate your hydrogel-based drug delivery projects, contact us at: sales@litchlab.com or visit www.litchlab.com
